Every 10-Q that JANEL CORP (JANL) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow JANL and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full JANL filings page.
Janel Corporation reported higher results for the quarter ended June 30, 2026. Total revenues were $67,512, up from $49,145 a year earlier, driven mainly by Logistics, which generated $61,081. Net income attributable to Janel was $2,097, and net income available to common stockholders was $1,983, or diluted EPS of $1.63 versus $0.67.
For the nine-month period, revenues reached $180,995 compared with $151,230 in 2025. Net income attributable to Janel was $3,233, and net income available to common stockholders was $2,907, or diluted EPS of $2.39. Operating cash flow was $20,134, supporting cash and cash equivalents of $33,697 as of June 30, 2026.
Total assets were $192,000, including goodwill of $31,592 and intangible assets of $37,374. The company completed several transactions, including consolidating Rubicon in the Manufacturing segment and acquiring an antibody product line and related royalty stream, and now operates under a new $59,120 credit facility with $13,929 drawn on the asset-based revolver and $9,668 on the acquisition revolver while remaining in covenant compliance.
Janel Corporation reported higher revenue but lower earnings and cash flow for the quarter ended March 31, 2026. Total revenue rose to $57,444 from $50,731 a year earlier, driven mainly by Logistics, where revenue increased to $51,484. Six‑month revenue reached $113,483 versus $102,085.
Despite stronger sales, net income available to common stockholders fell to $605 for the quarter and $924 for six months, down from $1,332 and $1,662, as operating expenses and interest costs increased. Diluted EPS for the quarter declined to $0.50 from $1.10.
Operating cash flow swung to an outflow of $9,696 for the first half of fiscal 2026, compared with an inflow of $7,067 a year earlier, largely reflecting reductions in accounts payable. Cash and cash equivalents were $8,785, while lines of credit outstanding grew to $17,845. The company continued executing its acquisition strategy, consolidating Rubicon Technology, increasing stakes in Biosensis, and, after quarter‑end, agreeing to acquire an antibody product line from BioPorto A/S for $9,000 plus potential earnouts.
Janel Corporation reported higher revenue but mixed profit and cash flow for the quarter ended December 31, 2025. Revenue rose 9.1% to $56.0 million, driven mainly by acquisitions in the Logistics and Life Sciences segments. Gross profit increased to $18.1 million from $15.1 million.
However, income from operations declined to $1.0 million from $1.2 million, and net income attributable to Janel fell to $0.4 million from $0.7 million. Net income attributable to common stockholders was $0.3 million, or $0.27 per diluted share, slightly below $0.28 a year earlier.
Logistics remained the growth engine, with revenue up to $50.8 million and operating income rising to $3.4 million on stronger margins and recent acquisitions. Life Sciences revenue grew but operating income decreased as new acquisition costs weighed on results. Manufacturing revenue and gross margin declined year over year.
Operating cash flow swung to an outflow of $14.5 million, mainly due to higher accounts receivable and lower payables. Janel refinanced its borrowing arrangements through a new $59.1 million credit facility, using the proceeds to repay $33.0 million of existing loans. Total assets reached $176.1 million and stockholders’ equity increased to $28.9 million.